Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
CytomX Therapeutics (CTMX) PT Raised to $37 at Wedbush Amid Amgen Collaboration
October 4, 2017 6:35 AM EDTWedbush analyst Robert Driscoll raised his price target on CytomX Therapeutics (NASDAQ: CTMX) to $37.00 (from $26.00) while maintaining a Outperform rating after the company added Amgen to its partner list with a new bispecifics collaboration.
Driscoll views bispecifics as an ideal application of the masking... More
